At Zentek, we develop new technologies and intellectual property by harnessing the power of nanotechnology and graphene to enhance our commercial partners' existing products making them safer, more effective, and more sustainable.
At Zentek, we develop new technologies and intellectual property by harnessing the power of nanotechnology and graphene to enhance our commercial partner’s existing products and create solutions that improve people’s lives by making them safer, more effective and more sustainable. With growing health and humanitarian challenges, the need to work together on innovative and novel solutions is stronger than ever. As we saw during the global pandemic, monumental challenges lead to solution-oriented collaboration and amazing breakthroughs. During the pandemic we did our best to contribute, focusing our energy and expertise on new ways to protect people. What resulted from the ingenuity and perseverance of our team and partners was the development of our ZenGUARD™ technology and broad-spectrum therapeutic compound, which we believe both hold significant promise to help people globally and create substantial value for our shareholders.
As an IP development and commercialization company, we are highly scalable with differentiated opportunities that we are actively exploring. We leverage university partnerships globally, have numerous patent applications to secure our IP, and a significant floor valuation with downside protection from our 100% ownership of the Albany Graphite Deposit.
Complex challenges require collaboration and novel solutions, and we believe nanotechnology and graphene will play an enormous role in meeting those challenges and many others. We are proud to work in an area that has incredible potential for our partners and our shareholders. We look forward to achieving more great things with our current partners and forging new relationships in the years ahead.
Greg Fenton
Chief Executive Officer, Director
Dr. Francis Dube, O.D., B.Sc.
Director & Executive Chairman